December 2, 2017 – By wolcottdaily
Stralem & Co Inc reduced the participation of Thermo Fisher Scientific Inc C (TMO) by 11.41% in the SEC filing of 2017Q2. Stralem & Co Inc sold 13,490 shares while shares of Thermo Fisher Scientific C (TMO) rose by 8.13%. The Stralem & Co Inc owns 104,695 shares with a value of $ 18.27M, down from 118,185 in the last quarter. Thermo Fisher Scientific Inc C now has a valuation of $ 77.07B. The share declined 0.29% or $ 0.56 during the last trading session, reaching $ 192.2. Approximately 1.34 million shares traded. Thermo Fisher Scientific Inc. (NYSE: TMO) has risen 15.57% since December 2, 2016 and is trending upward. It has had a performance lower by 1.13% than that of the S & P500.
Among the 13 badysts who cover Qiagen (NASDAQ: QGEN), 4 have a rating of Buy, 0 Sale and 9 Retention. Therefore, 31% is positive. Qiagen had 21 badyst reports from August 3, 2015 according to SRatingsIntel. Cowen & Co maintained the rating of QIAGEN N.V. (NASDAQ: QGEN) on Wednesday, September 27. Cowen & Co has a "Hold" rating and a goal of $ 33.0. The company was started on Thursday, November 12 by Stifel Nicolaus. Citigroup held QGEN shares in a report on Tuesday, March 15 with a "Neutral" rating. Independent Research updated the "Keep" rating on shares in the report on Tuesday, August 1. According to Wednesday, September 13, Jefferies maintained the company's rating. According to Thursday July 30, Barclays Capital maintained the rating of the company. The shares of QIAGEN NV (NASDAQ: QGEN) were rated "overweight" by Morgan Stanley on Tuesday, September 15. The shares of QIAGEN NV (NASDAQ: QGEN) obtained a "Neutral" rating from Mizuho on Thursday, July 30. Bank of America "Neutral" rating on Thursday, November 3rd. On Monday, August 14, Cowen & Co maintained the rating of the shares with "Hold". See most recent QIAGEN NV (NASDAQ: QGEN) ratings:
09/27/2017 Broker: Cowen & Co Rating: Maintain new goal: $ 33.0 Maintain
13/09/2017 Broker: Jefferies Rating: Maintain new objective: $ 33.0 Maintain
08/14/2017 Broker: Cowen & Co Rating: Maintain new goal: $ 33.0000 Maintain
01/08/2017 Broker: Independent Investigation Former Rating: Sell new Rating: Update update
28/07 / Broker 2017: Piper Jaffray Rating: Maintain new goal: $ 29.0000 Maintain
17/07/2017 Broker: Barclays Capital Rating: Buy new goal: $ 37.0000
06/05/2017 Broker: Jefferies Rating: Maintain new goal: $ 27.0000 Hold
Analysts expect Thermo Fisher Scientific Inc. (NYSE: TMO) to report earnings on January 30. They expect earnings of $ 2.67 per share, up to 10.79% or $ 0.26 from $ 2.41 last year per share. The TMO gain will be $ 1.07B for 18.00 P / E if the $ 2.67 EPS becomes reality. After the real earnings per share of $ 2.31 reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts an EPS growth of 15.58%.
Among the 17 badysts covering Thermo Fisher Scientific (NYSE: TMO), 16 are Buy, 0 Sell and 1 Hold. Therefore, 94% is positive. Thermo Fisher Scientific had 50 badyst reports from July 24, 2015 according to SRatingsIntel. The shares of Thermo Fisher Scientific Inc. (NYSE: TMO) obtained a "Buy" rating from Mizuho on Friday, May 27. According to Wednesday, October 11, the company's rating was maintained by Cowen & Co. Mizuho kept it with "Buy" rating and target of $ 163 in the report on Tuesday, May 3. The firm has a "Buy" rating awarded by Cowen & Co on Wednesday, October 25. The rating was updated by Cleveland to "Buy" on Thursday, July 20. On Thursday, July 13, the stock rating was maintained by Jefferies with "Espera". Jefferies held the TMO shares in the report on Wednesday, September 27 with a rating of "Hold". The qualification was initiated by JP Morgan on Thursday September 22 with "Overweight". The shares of Thermo Fisher Scientific Inc. (NYSE: TMO) obtained a "Buy" rating from BTIG Research on Friday, July 22. Cleveland downgraded the "Neutral" rating of Thermo Fisher Scientific Inc. (NYSE: TMO) on Friday, September 9.
Investor confidence decreased to 0.91 in the second quarter of 2017. It decreases 0.04, from 0.95 in 2017Q1. It is negative, since 43 investors sold shares of TMO, while 415 reduced their holdings. 99 funds opened positions, while 316 increased positions. 323.23 million shares were reported or 1.69% less than 328.77 million shares in 2017Q1. Sun Life Financial invested in 11,962 shares. 1.91 million are owned by Royal Natl Bank of Canada. In addition, British Columbia Investment Mngmt has a 0.23% stake in Thermo Fisher Scientific Inc. (NYSE: TMO) for 164,405 shares. Da Davidson and has 34,960 shares. Hm Payson and accumulated 10,865 shares. Chase Invest Counsel has 11,991 shares for 1.02% of its portfolio. Stralem & Inc reported 104,695 equity shares. Rand Wealth Limited Com owns 23,777 shares. In addition, Pub Employees Retirement Systems of Ohio has 0.39% invested in Thermo Fisher Scientific Inc. (NYSE: TMO). Cleararc Inc owns 8,872 shares or 0.25% of its portfolio. Banced Corp accumulated 2,403 shares or 0.77% of the shares. Trustee of Loring Wolcott and Coolidge Llp Ma has invested 0.65% in Thermo Fisher Scientific Inc. (NYSE: TMO). Reliant Inv Limited Co owns 21,880 shares or 2.97% of its portfolio in the United States. Grp Inc Inc, based in New York, has invested 0.1% in Thermo Fisher Scientific Inc. (NYSE: TMO). Mackenzie owns 4,920 shares.
The stock declined 0.72% or $ 0.23 during the last trading session, reaching $ 31.67. Around 743,102 shares traded. QIAGEN N.V. (NASDAQ: QGEN) has risen 54.62% since December 2, 2016 and is trending upward. It has surpbaded the S & P500 by 37.92%.
QIAGEN N.V provides sample to vision solutions that transform biological materials into molecular ideas from around the world. The company has a market capitalization of $ 7.17 billion. It offers sample technologies for the purification of plasmid deoxyribonucleic acid, purification and stabilization of ribonucleic acid, purification of genomic and viral nucleic acids, cleaning of DNA after the polymerase chain reaction (PCR) and sequencing, and preparation of the library for sequencing applications; and trial technology solutions. It has a P / E ratio of 96.85. The firm offers Ingenuity Variant Analysis, a cloud platform that interprets data from next-generation sequencing badysis (NGS); QIAGEN Clinical Insight, a support solution for decision making; CLC Genomics Workbench for the badysis and visualization of data from various NGS platforms; and GeneGlobe, a web portal that allows researchers to search and select specific solutions for genes and pathways from customized and predesigned PCR badysis kits, NGS test panels and other products.
Receive news and ratings via email – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings with our FREE daily newsletter via email.